QC
BTAI icon

Quadrature Capital’s BioXcel Therapeutics BTAI Stock Holding History

Quadrature Capital’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.6K Buy
+38,038
New +$44.6K ﹤0.01% 1509

Other funds holding BTAI

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $1.02B AUM 45.95% 1-Year Est. Return

Quadrature Capital's BTAI Position: Q2 2026 in Review

Quadrature Capital opened a new position in BioXcel Therapeutics (BTAI) in Q2 2026: 38,038 shares worth $53.6K. The stake represents ﹤0.01% of the portfolio and ranks #1509 among its holdings.

32 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

  • Quadrature Capital held 38,038 shares of BioXcel Therapeutics worth $53.6K as of Q2 2026.
  • BioXcel Therapeutics was a new Quadrature Capital position in Q2 2026.
  • BioXcel Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1509 holding.
  • 32 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.